Sign in
Randomized, dose-escalation study of the p38 alpha MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome
Journal article   Peer reviewed

Randomized, dose-escalation study of the p38 alpha MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome

L. Sokol, L. Cripe, H. Kantarjian, M. A. Sekeres, S. Parmar, P. Greenberg, S. L. Goldberg, V. Bhushan, J. Shammo, R. Hohl, …
Leukemia, Vol.27(4), pp.977-980
2013-04-01
PMID: 23032694

Abstract

Hematology Life Sciences & Biomedicine Oncology Science & Technology

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Industry collaboration
Domestic collaboration
Citation topics
1 Clinical & Life Sciences
1.103 Blood Disorders
1.103.155 Acute Myeloid Leukemia
Web Of Science research areas
Hematology
Oncology
ESI research areas
Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Details